1. Home
  2. BLTE vs AMPH Comparison

BLTE vs AMPH Comparison

Compare BLTE & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLTE
  • AMPH
  • Stock Information
  • Founded
  • BLTE 2018
  • AMPH 1996
  • Country
  • BLTE United States
  • AMPH United States
  • Employees
  • BLTE N/A
  • AMPH N/A
  • Industry
  • BLTE Biotechnology: Pharmaceutical Preparations
  • AMPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • BLTE Health Care
  • AMPH Health Care
  • Exchange
  • BLTE Nasdaq
  • AMPH Nasdaq
  • Market Cap
  • BLTE 2.1B
  • AMPH 2.5B
  • IPO Year
  • BLTE 2022
  • AMPH 2014
  • Fundamental
  • Price
  • BLTE $64.12
  • AMPH $39.54
  • Analyst Decision
  • BLTE Strong Buy
  • AMPH Buy
  • Analyst Count
  • BLTE 4
  • AMPH 4
  • Target Price
  • BLTE $89.00
  • AMPH $60.33
  • AVG Volume (30 Days)
  • BLTE 62.6K
  • AMPH 611.1K
  • Earning Date
  • BLTE 11-12-2024
  • AMPH 11-06-2024
  • Dividend Yield
  • BLTE N/A
  • AMPH N/A
  • EPS Growth
  • BLTE N/A
  • AMPH 17.38
  • EPS
  • BLTE N/A
  • AMPH 3.01
  • Revenue
  • BLTE N/A
  • AMPH $723,549,000.00
  • Revenue This Year
  • BLTE N/A
  • AMPH $16.76
  • Revenue Next Year
  • BLTE N/A
  • AMPH $9.34
  • P/E Ratio
  • BLTE N/A
  • AMPH $13.01
  • Revenue Growth
  • BLTE N/A
  • AMPH 20.33
  • 52 Week Low
  • BLTE $31.01
  • AMPH $36.56
  • 52 Week High
  • BLTE $86.53
  • AMPH $65.92
  • Technical
  • Relative Strength Index (RSI)
  • BLTE 44.50
  • AMPH 30.89
  • Support Level
  • BLTE $60.00
  • AMPH $38.78
  • Resistance Level
  • BLTE $76.87
  • AMPH $45.39
  • Average True Range (ATR)
  • BLTE 4.51
  • AMPH 1.36
  • MACD
  • BLTE -0.44
  • AMPH -0.34
  • Stochastic Oscillator
  • BLTE 24.42
  • AMPH 15.69

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

About AMPH Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Share on Social Networks: